Albuterol Sulfate
Total Payments
$4.6M
Transactions
1,921
Doctors
17
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $833.07 | 16 | 13 |
| 2023 | $212,774 | 443 | 4 |
| 2022 | $1.2M | 270 | 2 |
| 2021 | $3.2M | 1,192 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 1,905 | 100.0% |
| Food and Beverage | $833.07 | 16 | 0.0% |
Payments by Type
Research
$4.6M
1,905 transactions
General
$833.07
16 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | Teva Pharmaceuticals USA, Inc. | $3.0M | 2 |
| CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | Teva Pharmaceuticals USA, Inc. | $1.1M | 1 |
| Use of ProAir Digihaler in COPD - Characterization of inhalation parameters from a cohort of patient at-risk for AECOPD in an outpatient setting | Teva Pharmaceuticals USA, Inc. | $253,802 | 0 |
| Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma | Teva Pharmaceuticals USA, Inc. | $115,730 | 0 |
| A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | Teva Pharmaceuticals USA, Inc. | $59,557 | 2 |
| Albuterol Integrated Adherence Monitoring in Children with Asthma | Teva Pharmaceuticals USA, Inc. | $15,472 | 0 |
| A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma | Teva Pharmaceuticals USA, Inc. | $9,539 | 0 |
| ProAir Digihaler in COPD Disease Management: A real world study to assess ProAir Digihaler inhalation parameters thresholds and their use to identify deterioration in clinical practice_ | Teva Pharmaceuticals USA, Inc. | $8,800 | 0 |
Top Doctors Receiving Payments for Albuterol Sulfate
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $4.5M | 1,869 |
| , MD | Allergy & Immunology | Bangor, ME | $14,386 | 15 |
| , MD | Allergy | Oklahoma City, OK | $13,578 | 8 |
| , M.D | Allergy | Sarasota, FL | $10,281 | 6 |
| , M.D | Family Medicine | Dallas, TX | $8,409 | 7 |
| , M.D | Allergy & Immunology | Bowling Green, KY | $109.94 | 2 |
| , M.D | Specialist | Birmingham, AL | $109.94 | 2 |
| , MD | Allergy & Immunology | Houston, TX | $109.93 | 2 |
| , MD | Internal Medicine | Birmingham, AL | $70.42 | 1 |
| , MD | Internal Medicine | Dearborn, MI | $70.42 | 1 |
| William Fancher | Allergy | Turnersville, NJ | $70.41 | 1 |
| , MD | Allergy & Immunology | Baytown, TX | $70.41 | 1 |
| , M.D | Allergy & Immunology | Clarksville, MD | $39.53 | 1 |
| , MD | Allergy & Immunology | Charlotte, NC | $39.53 | 1 |
| , MD | Allergy & Immunology | New York, NY | $39.52 | 1 |
| , RN, MS, CRNP | Nurse Practitioner | Alabaster, AL | $39.52 | 1 |
| , M.D | Specialist | Mukwonago, WI | $31.75 | 1 |
| , NP | Family | Mount Pleasant, WI | $31.75 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.6M
- Total Doctors 17
- Transactions 1,921
About Albuterol Sulfate
Albuterol Sulfate is a drug associated with $4.6M in payments to 17 healthcare providers, recorded across 1,921 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2021 to 2024. In 2024, $833.07 was paid across 16 transactions to 13 doctors.
The most common payment nature for Albuterol Sulfate is "Unspecified" ($4.6M, 100.0% of total).
Albuterol Sulfate is associated with 8 research studies, including "CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma" ($3.0M).